AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02799784
Drug: TIO/OLO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
Trial: NCT01291914
Drug: Placebo 1 (Carrier)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection
Trial: NCT01291914
Drug: Placebo 2 (Diluent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection
Trial: NCT02644629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
Trial: NCT04594226
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
Trial: NCT02000336
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
Trial: NCT02000336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00674570
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg/oral one hour prior to extinction task
Trial: NCT00674570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour prior to extinction task
Trial: NCT01725269
Drug: AIR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Trial: NCT04077957
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
Trial: NCT01551602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple administration of placebo AK159
Trial: NCT01499225
Drug: YH14642 500mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH14642 500mg per day(once a day)
Trial: NCT01499225
Drug: YH14642 500mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH14642 1000mg per day(twice a day)
Trial: NCT01499225
Drug: YH14642 500mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH14642 2000mg per day(three times a day)
Trial: NCT01499225
Drug: INSADOL[Zea mays L. extract] 35mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day
Trial: NCT01499225
Drug: DENTISTA[Doxycycline hyclate] 20mg Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
Trial: NCT01499225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04033250
Drug: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation
Trial: NCT02130804
Drug: Salsalate (4 g/day)
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally twice daily
Trial: NCT02130804
Drug: Placebo (4 g/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally twice daily
Trial: NCT03080350
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual
Trial: NCT03080350
Drug: Fentanyl ev
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl ev
Trial: NCT03080350
Drug: Placebo sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual
Trial: NCT03080350
Drug: Placebo ev
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - NaCL 0,9% ev
Trial: NCT00076752
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
Trial: NCT04108104
Drug: Alpress LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month treatment
Trial: NCT02817516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-828 placebo-matching solution.
Trial: NCT00832442
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as determined by individual study
Trial: NCT03472456
Drug: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Trial: NCT03727152
Drug: generic single tablet TAF/FTC/DTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
Trial: NCT02557932
Drug: Standard triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
Trial: NCT02426723
Drug: Phase 1a: CWP232291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CWP232291 administered alone twice weekly every 4 weeks.
Trial: NCT04026165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT02637895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill matching Vortioxetine.
Trial: NCT02360319
Drug: Any FDA approved antipsychotic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators are free to choose the most appropriate treatment for their clients
Trial: NCT03471169
Drug: Undesirable TEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Trial: NCT01363752
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. and oral
Trial: NCT03562611
Drug: Nalbuphine and Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Trial: NCT03645746
Drug: REGN5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN5069 will be administered by IV infusion or SC injection
Trial: NCT03645746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching REGN5069
Trial: NCT01675570
Drug: RX-10045
RxNorm normalized name: BARRIER,SENSURA COLOPLAST #10045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Trial: NCT02500147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
Trial: NCT04448561
Drug: ASP8082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04448561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02976779
Drug: OWC Control Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cream without active ingredients
Trial: NCT00782184
Drug: ezetimibe/simvastatin 10/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
Trial: NCT03830684
Drug: blank control 0mg
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo per time, three times a day
Trial: NCT04387630
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 60 mg three times daily.
Trial: NCT01302444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks
Trial: NCT02360631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education counseling will be provided to all participants.
Trial: NCT00857168
Drug: Testosterone MD-Lotion
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02689869
Drug: GA 101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Trial: NCT01606527
Drug: Ibuprofen 600mg orally three times daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibuprofen is taken 600mg orally three times daily
Trial: NCT02912260
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02912260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01614782
Drug: MK-5823
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.
Trial: NCT01889186
Drug: ABT-199 (Main Cohort)
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
Trial: NCT01889186
Drug: ABT-199 (Safety Expansion Cohort)
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
Trial: NCT03575299
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
Trial: NCT02103959
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow bolus IV administration of PBS
Trial: NCT02822573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Trial: NCT03891862
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active dosage form
Trial: NCT02855359
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Trial: NCT02855359
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Trial: NCT00262470
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 25-50 mg PO x 1 dose
Trial: NCT01023256
Drug: MOR103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR103 0.3 mg/kg or placebo iv x 4 doses
Trial: NCT01023256
Drug: MOR103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR103 1.0 mg/kg or placebo iv x 4 doses
Trial: NCT01023256
Drug: MOR103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR103 1.5 mg/kg or placebo iv x 4 doses
Trial: NCT01971164
Drug: JTZ-951
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive JTZ-951 or Placebo
Trial: NCT01245543
Drug: AC480IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC480IV will be administered as an infusion using a dose escalation design.
Trial: NCT04430842
Drug: QBS10072S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBS10072S targets cancers with high LAT1 expression.
Trial: NCT02197286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of a single gelatin placebo capsule.
Trial: NCT03589326
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate IV infusion.
Trial: NCT01971164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02288091
Drug: Inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
Trial: NCT00987870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03435952
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
Trial: NCT04537910
Drug: LY3819253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04537910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02349919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 4 weeks
Trial: NCT01658124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03596723
Drug: KPI-121 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT03596723
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT02569437
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
Trial: NCT00438737
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00438737
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00792688
Drug: GLYC-101 Gel (0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Trial: NCT00792688
Drug: GLYC-101 Gel (1.0%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Trial: NCT00792688
Drug: GLYC-101 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Trial: NCT03651427
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induced hypogonadism and re-institution of CSHT
Trial: NCT02320773
Drug: Betmiga®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02091479
Drug: UFH Early group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Trial: NCT02091479
Drug: UFH Late group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Trial: NCT04074590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule for oral use
Trial: NCT00908089
Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
Trial: NCT00199797
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
Trial: NCT00660075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks
Trial: NCT00435279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01265602
Drug: LAS41007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Trial: NCT01265602
Drug: LASW1510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Trial: NCT03892577
Drug: Precision oncology including targeted therapy and immunotherapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
Trial: NCT01953874
Drug: Optimized Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated